Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

September 5, 2022

Study Completion Date

September 6, 2022

Conditions
Central Nervous System Pathology
Interventions
DRUG

Gadoquatrane (BAY1747846)

Solution for IV injection, single dose

DRUG

Gadobutrol (Gadovist/Gadavist)

Solution for IV injection, single dose

Trial Locations (17)

1407

Acibadem City Clinic Multiprofile Hospital for Active Treatm, Sofia

1431

University Multiprofile Hosp. for Active Treat. Sveti Ivan, Sofia

4002

UMHAT Sveti Georgi, Plovdiv

17033

Penn State Milton S. Hershey Medical Center, Hershey

44263

MVZ Prof. Uhlenbrock und Partner, Dortmund

45147

Universitätsklinikum Essen, Essen

60611

Northwestern University, Chicago

52242-1089

University of Iowa Hospitals & Clinics, Iowa City

07740

Friedrich-Schiller-Uni. Jena, Jena

060-8648

Hokkaido University Hospital, Sapporo

670-8520

National Hospital Organization Himeji Medical Center, Himeji

662-0918

Hyogo Prefectural Nishinomiya Hospital, Nishinomiya

596-0042

Kishiwada Tokushukai Hospital, Kishiwada

752-8510

National Hospital Organization Kanmon Medical Center, Shimonoseki

810-8563

National Hospital Organization Kyushu Medical Center, Fukuoka

811-0213

Social Medical Corporation the Chiyukai foundation Fukuoka Wajiro Hospital, Fukuoka

730-8518

Hiroshima City Hiroshima Citizens Hospital, Hiroshima

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY